Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.
Alexander E DrilonMichael DuruisseauxJi-Youn HanMasaoki ItoChristina J FalconSoo-Ryum YangYonina R Murciano-GoroffHaiquan ChenMorihito OkadaMiguel Ángel Molina-VilaMarie WislezPhilippe BrunClarisse DupontEva BrandenGiulio RossiAlexa B SchrockSiraj M AliValérie GounantFanny MagneTorsten Gerriet BlumAlison M SchramIsabelle MonnetJin-Yuan ShihJoshua K SabariMaurice PérolViola W ZhuMisako NagasakaRobert DoebeleD Ross CamidgeMaria ArcilaSai-Hong Ignatius OuDenis Moro-SibilotRafael RosellLucia Anna MuscarellaStephen V LiuJacques CadranelPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
NRG1 fusion-positive lung cancers were molecularly, pathologically, and clinically more heterogeneous than previously recognized. The activity of cytotoxic, immune, and targeted therapies was disappointing. Further research examining NRG1-rearranged tumor biology is needed to develop new therapeutic strategies.